English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/184041
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Lactibiane iki treatment increases regulatory T cell and improves experimental autoimmune encephalomyelitis outcome

AuthorsCalvo-Barreiro, L.; Eixarch, H.; Costa, C.; Castillo, M. ; Mestre, Leyre ; Guaza, Carmen ; Montalbán, Xavier
Issue DateOct-2018
Citation34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (2018)
AbstractMultiple sclerosis (MS) is a chronic, inflammatory, demyelinating and degenerative disease that affects the central nervous system (CNS). MS development depends on genetic and environmental factors. Thus, genetically predisposed individuals are thought to develop MS after exposure to different environmental factors. Recently, the commensal microbiota has emerged as a novel environmental risk factor primarily as a result of data from research in experimental autoimmune encephalomyelitis (EAE) models1. Experimental data support the idea that some bacterial strains could have a beneficial impact on EAE development. Thus, microbiota modulation by probiotics is being developed as the primary EAE therapeutic strategy involving the gut microbiota2. Lactibiane iki is a commercial multispecies probiotic composed by Lactobacillus acidophilus, Lactobacillus salivarius and bifidobacterium lactis. Two of its three bacterial strains have previously proved their in vitro immunomodulatory properties by stimulating IL-10 cytokine expression3. Likewise, they have proved efficacy in another autoimmunity disease such as experimental colitis3. In this study, we aimed to investigate the impact of the treatment with Lactibiane iki on the clinical outcome of EAE and its mechanisms of action.
DescriptionTrabajo presentado en el 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECCTRIMS2018), celebrado en Berlín del 10 al 12 de octubre de 2018.
URIhttp://hdl.handle.net/10261/184041
Appears in Collections:(IC) Comunicaciones congresos
Files in This Item:
File Description SizeFormat 
lactibiane.pdf1,06 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.